RNAC Earnings Date: Nov 5, 2026 (Estimated) — Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RNAC's next earnings date?
Cartesian Therapeutics, Inc. (RNAC) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.02 on revenue of $160,000.
How did RNAC do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Cartesian Therapeutics, Inc. posted EPS of $0.46 versus the -$0.88 estimate, a beat of 167.7%. Revenue was $0 against a $179,667 estimate. The stock's 1-day post-earnings move was +4.9%.
How much does RNAC stock move after earnings?
RNAC beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.88 | 0.46 | +167.65% | $0 | ✅ Beat | +4.91% | +3.89% | +9.22% |
| 2026-04-30 | Q1 2026 | -0.73 | -1.46 | -100.00% | $78,000 | ❌ Miss | -3.86% | +28.90% | +16.54% |
| 2026-03-09 | Q4 2025 | -0.80 | -1.39 | -73.75% | $947,000 | ❌ Miss | +31.68% | +7.88% | -8.32% |
| 2025-11-06 | Q3 2025 | -0.70 | -1.38 | -97.14% | $452,000 | ❌ Miss | -1.56% | -1.17% | -10.30% |
| 2025-03-13 | Q4 2024 | -0.83 | -0.40 | +51.81% | $-759,000 | ✅ Beat | -4.98% | -11.56% | -40.73% |
| 2024-11-07 | Q3 2024 | -0.73 | -1.13 | -54.79% | $387,000 | ❌ Miss | -0.38% | -17.93% | +20.52% |
| 2024-05-08 | Q1 2024 | -0.88 | -10.50 | -1093.18% | $5.8M | ❌ Miss | +0.19% | +6.66% | +49.54% |
| 2024-03-07 | Q4 2023 | -0.90 | -41.70 | -4533.33% | $8.3M | ❌ Miss | -8.05% | -21.43% | -36.62% |
Showing last 8 quarters.